The Genetics Reports Bundle includes the following TriMark Publications reports at a 15% discount off the individual reports being purchased separately:
- Bioinformatics Markets.
- DNA Sequencing and PCR Markets.
- Gene Expression Reagents Markets.
- Genomics World Markets.
- Microarray Markets.
- Personalized Medicine.
- Pharmacogenomics for Clinical Use and in Drug Development.
- Regenerative Medicine Markets.
- RNA Interference Markets.
- Stem Cell Markets.
Below are summaries of each report, along with a link to download a product sample which includes: detailed table of contents, writer's background, executive summary, report methodology and sample pages. All Report Bundles are available for purchase by invoice directly from TriMark. Add to cart and follow purchasing directions.
The life science informatics marketplace--known as bioinformatics--is set to expand as high-tech companies infiltrate this arena and biopharmaceutical companies incorporate key informatic solutions into their business strategies. TriMark Publications believes that many of the segments of bioinformatics described in this report offer an unusual opportunity for accelerated expansion within the coming years. This study is arranged to provide an overview of bioinformatics market segments and offer evidence that these segments are poised for significant future growth. Each segment is accompanied by analysis and forecasts by product type and application. This analysis surveys the bioinformatics market and the latest information regarding emerging new products and industry trends. The study will quantify and qualify the bioinformatics market segments as an area of research, product development and investment. Forecasts of the bioinformatics market and an analysis of products in the worldwide information-processing market will provide a basis for understanding the significance of past developments and future possibilities within this market category.
The focus of this TriMark Publications report is to describe the specific segment of the life sciences market called DNA sequencing. This analysis includes all of the generally-accepted DNA-oriented analytical activities that are currently used today, such as enabling technologies like polymerase chain reaction (PCR). It examines these measurement technology platforms and their reagents and supplies as utilized in biotechnology research, pharmacology and healthcare. Generally, diagnostic tests which are marketed primarily as over-the-counter products directly to patients are not included in this study, although there is inevitably some overlap. This examination will: 1) identify viable technology drivers through a comprehensive look at various platform technologies for molecular sequencing, including immunoassays electrophoretic methods, probe-based nucleic acid assays, microarrays and non-PCR sequencing; 2) obtain a complete understanding of the chief molecular sequencing tests for predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic applications; 3) discover feasible market opportunities via an identification of high-growth applications in different therapeutic areas, with a focus on the biggest and expanding markets-communicable diseases, cardiology and oncology; and 4) focus on global industry development through an in-depth analysis of the major world markets for molecular sequencing, including forecasts for growth.
The area of gene expression reagents is one of the newest and most important sectors of pharmaceutical and bioscience research and development. The term gene expression reagents refers to chemicals that are used in gene expression experiments that are performed to determine whether a particular gene is expressed--i.e., present--and in some cases at what levels, in a biological sample. The purpose of this TriMark Publications report is to describe the specific segments of the global gene expression reagents market. Within this area, the study covers those segments that are highly active in terms of innovation and growth. Specifically, this review examines the markets for gene expression reagents and small lab equipment all the way up to highly automated platforms. Emphasis is on those companies that are actively developing and marketing gene expression reagents for genomics research in the academic sector and the pharmaceutical, bioscience industry. This study concentrates on the laboratory reagent market segment and the companion gene expression reagents sector in the U.S. and around the world that use materials for genetic research. Particular attention is paid to those areas of the gene expression reagents sector that are showing the greatest growth or the most innovation.
Genomics is transforming the pharmaceutical industry. Companies are moving from drug discovery and development based on medicinal chemistry to the design of drugs based on information provided by genomics. Virtually all of the major pharmaceutical houses have either formed partnerships with genomics firms that began to emerge in the early 1990s or have created in house genomics divisions. The aim of this TriMark Publications study is to provide in depth information on the developing market for genomics products and services. The report will include detailed market analyses and discussions of industry trends in order to assess the impact of genomics on the current and emerging pharmaceutical and diagnostic markets. Forecasts and trends were developed from interviews with industry sources, as well as from an assessment of available and emerging technologies. The report focuses on how researchers are applying new genomic approaches to drug discovery and development, and on how these technologies can be used most effectively and in a high throughput capacity. Case studies analyzing particular applications of genomic technologies to specific disease related research are provided, and future trends and developments are forecasted. Information to prepare this study was derived from interviews with product managers, marketing strategists, research executives and others. These individuals are employed at leading genomics firms or in pharmaceutical and biotechnology companies that either contract with these firms or have developed in house genomics capabilities.
A microarray is an arrangement of miniaturized test sites or "spots" on a surface. Each spot is usually no more than 250 micrometers in diameter and contains biological molecules--usually DNA or protein--which act as probes for a test sample applied to the array. The surface may be a glass slide, a plastic plate with wells or a polymer bead. The microarray format allows many tests or experiments to be performed simultaneously, in parallel, leading to the generation of huge amounts of biological information for the application of only a tiny amount of sample. Microarrays are often also known as "biochips". The purpose of this TriMark Publications report is to describe the specific segment of the microarray market aimed at analysis of proteins and DNA. Protein microarray applications include: 1) expression profiling; 2) serum-based diagnostics; 3) protein-protein binding assays; 4 drug-target binding; and 5) receptor epitope binding. It examines the market for DNA and protein array testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs, and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the protein array market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.
Personalized medicine and pharmacogenomics are inextricably linked. Pharmacogenomics is the use of genetic variations (such as SNPs, gene expression variability, or other molecular signatures) to understand and correlate with differential response to pharmaceutical agents (drugs). Pharmacogenomics can be deployed clinically to stratify patients into responders and non-responders and this practice is termed personalized medicine. The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics market called personalized medicine. To frame the context of current approaches, pharmacogenomics seeks to identify and validate the signature(s) of molecular analytes and these are converted to assays using the tools of molecular diagnostics. The deployment of these molecular diagnostics assays on defining and targeting patient populations is the domain of personalized medicine. This study includes all of the generally-accepted imaging activities that are currently used in personalized medicine, including pharmacogenomics, genomics and theranostics. It examines associated clinical market segments in which personalized medicine has taken a prominent role including cancer treatment, cardiology and neurology markets.
Pharmacogenomics, the science of individualizing drug therapy based on the genetic makeup of individual patients, offers an unusual opportunity for future market growth. Applying pharmacogenomics would allow doctors to treat specific segments of the population based on their particular responses to a drug. The knowledge of the likely effectiveness of a drug in a patient makes the drug more reliable, and fewer drugs would have to be taken off the market due to adverse reactions in some, but not all, of the patients to whom they were administered. Additionally, reducing the occurrence of adverse effects to a drug effectually reduces the cost of patient care overall. This TriMark Publications study examines the market for diagnostic tests based on this science and the clinical measurement methods, the reagents and supplies being utilized in clinical medicine and the pharmaceutical industry. This report presents an overview of the latest information regarding emerging new products and industry trends and will not only quantify, but also, qualify the pharmacogenomic market segments as an area of research, product development and investment opportunity. Forecasts of the pharmacogenomic market and an analysis of products in the worldwide diagnostics market will provide a basis for understanding the significance of past developments and the immense possibilities of the future.
Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine. This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures. The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.
Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this TriMark Publications report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing. The main objectives of this study are to: 1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment; 2) obtain a complete understanding of the individual RNAi-testing platforms--from basic principles to clinical applications; 3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets; 4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts; and 5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.
A stem cell is an extraordinary type of cell that has the ability to self-renew for long periods of time and to differentiate into specialized cells under appropriate physiological or experimental conditions. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. Recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. The purpose of this TriMark Publications report is to describe the specific market segments of the medical research space using stem cells for research and development purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. It examines the use of stem cells in developing new therapies for disease.